Non-traditional drug targets: high risk, high reward.
Genomics and proteomics have unveiled a plethora of protein-protein interactions that may control cellular processes involved in disease development. Many of these interactions involve non-traditional candidate targets (i.e., neither enzymes nor cell surface receptors/channels). To date, non-traditional targets have largely been ignored by the pharmaceutical industry or have failed to lead to drugs. This review focuses on the use of transdominant genetically encoded agents and specialized small-molecule drugs to explore this void.
Sandrock
Tanya
T
Deltagen Proteomics, Lake City, UT 84124, USA. alexander.kamb@pharma.novartis.com
Kamb
Alexander
A
D000595:Amino Acid Sequence; D020134:Catalytic Domain; D023281:Genomics; D006801:Humans; D008969:Molecular Sequence Data; D011485:Protein Binding; D011506:Proteins / Q000037:antagonists & inhibitors / Q000737:chemistry / Q000235:genetics / Q000378:metabolism / Q000502:physiology*; D040901:Proteomics; D017386:Sequence Homology, Amino Acid
D011506:Proteins